Does Prothena Have A Best-In-Class Alzheimer’s Drug Waiting In The Wings?
Candidate 20 Times More Potent Than Leqembi In Preclinical Studies
Executive Summary
More than 20 years since its forerunner tried to develop the first anti-amyloid drug, Prothena’s CEO tells Scrip about its hopes for producing a best-in-class subcutaneous treatment for Alzheimer’s disease.